表紙
市場調查報告書

溶酶體酸性解脂酵素缺損症(LAL-D)市場分析·規模·佔有率·趨勢·預測 (2020-2026年) :治療藥·適應症·地區

Lysosomal Acid Liapse Deficiency Treatment Market, By Treatment, By Indication, and By Geography - Analysis, Share, Trends, Size, & Forecast From 2020 - 2026

出版商 AnalystView Market Insights 商品編碼 941385
出版日期 內容資訊 英文 158 Pages
商品交期: 2-3個工作天內
價格
溶酶體酸性解脂酵素缺損症(LAL-D)市場分析·規模·佔有率·趨勢·預測 (2020-2026年) :治療藥·適應症·地區 Lysosomal Acid Liapse Deficiency Treatment Market, By Treatment, By Indication, and By Geography - Analysis, Share, Trends, Size, & Forecast From 2020 - 2026
出版日期: 2020年06月01日內容資訊: 英文 158 Pages
簡介

溶酶體酸性解脂酵素缺損症(LAL-D)市場在2019年估算為3億9,050萬美元,以2020∼2026年的預測期間內,預計將以9.9%增長。

本報告提供全球溶酶體酸性解脂酵素缺損症(LAL-D)市場相關調查分析,提供市場概要,市場規模與預測,各市場區隔的市場分析,各地區的市場分析,競爭情形等相關的系統性資訊。

第1章 溶酶體酸性解脂酵素缺損症(LAL-D)市場概要

  • 調查範圍
  • 前提條件與調查手法

第2章 摘要整理

  • 市場明細
    • 市場明細:各治療藥物
    • 市場明細:各適應症
    • 市場明細:各地區
  • 競爭考察

第3章 溶酶體酸性解脂酵素缺損症(LAL-D)的主要的市場趨勢

  • 市場成長促進因素
    • 市場成長要素的影響分析
  • 阻礙市場成長要素
    • 阻礙市場成長要素的影響分析
  • 市場機會
  • 市場未來趨勢

第4章 溶酶體酸性解脂酵素缺損症(LAL-D)產業的調查

  • 波特的五力分析
  • 行銷策略分析
  • 成長預測製圖
  • 法律規範分析
  • COVID-19影響分析
    • COVID-19以前的影響分析
    • COVID-19以後的影響分析

第5章 溶酶體酸性解脂酵素缺損症(LAL-D)的市場形勢

  • 市場佔有率分析
  • 主要創新者
  • 分析資料:各主要製造商
    • 現有企業分析
    • 新興企業分析

第6章 溶酶體酸性解脂酵素缺損症(LAL-D)的市場:各治療法

  • 概要
    • 市場區隔佔有率分析:各治療法
  • 脂質修飾劑 (Statin)
    • 概要
    • 市場分析·預測·與前一年同期比較成長率
  • 酵素補充療法 (ERT)
  • 幹細胞療法
  • 支持療法
  • 外科手術

第7章 溶酶體酸性解脂酵素缺損症(LAL-D)的市場:各適應症

  • 概要
    • 市場區隔佔有率分析:各適應症
  • 膽固醇酯積蓄症(CESD)
    • 概要
    • 市場分析·預測·與前一年同期比較成長率
  • 沃爾曼病(WD)
  • 其他

第8章 溶酶體酸性解脂酵素缺損症(LAL-D)市場:各地區

  • 簡介
    • 市場區隔佔有率分析:各地區
  • 北美
    • 概要
    • 北美的主要製造商
    • 北美的市場規模與預測:各國
    • 北美的市場規模與預測:各治療法
    • 北美的市場規模與預測:各適應症
    • 美國
    • 加拿大
  • 歐洲
    • 概要
    • 歐洲的主要製造商
    • 歐洲的市場規模與預測:各國
    • 歐洲的市場規模與預測:各治療法
    • 歐洲的市場規模與預測:各適應症
    • 德國
    • 義大利
    • 英國
    • 法國
    • 其他歐洲
  • 亞太地區(APAC)
    • 概要
    • 亞太地區的主要製造商
    • 亞太地區的市場規模與預測:各國
    • 亞太地區的市場規模與預測:各治療法
    • 亞太地區的市場規模與預測:各適應症
    • 印度
    • 中國
    • 日本
    • 韓國
    • 亞太地區的其他各國
  • 南美
    • 概要
    • 南美的主要製造商
    • 南美的市場規模與預測:各國
    • 南美的市場規模與預測:各治療法
    • 南美的市場規模與預測:各適應症
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他南美國家
  • 中東·非洲
    • 概要
    • 中東·非洲的主要製造商
    • 中東·非洲的市場規模與預測:各國
    • 中東·非洲的市場規模與預測:各治療法
    • 中東·非洲的市場規模與預測:各適應症
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第9章 主要供應商分析

  • AstraZeneca plc.
    • 企業概況
    • 財務實際成果
    • 材料的基準
    • 策略性配合措施
  • Alexion Pharmaceutical Inc.
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.

第12章 分析師全方位展望

第13章 附錄

目錄

REPORT HIGHLIGHT

Lysosomal Acid Liapse (LAL) Deficiency Treatment market was valued at USD 390.5 million by 2019, growing with 9.9% CAGR during the forecast period, 2020-2026

Market Dynamics

The growing adoption of enzyme replacement therapy for treatment is one of the major factors driving the growth of global lysosomal acid lipase deficiency (LAL-D) treatment market. In addition, large patient pool and high prevalence of lysosomal acid lipase deficiency are other factors boosting the market growth. LAL-D is a rare type of lysosomal storage disorder, wherein patients are not able to triglycerides and cholesteryl esters due to a mutation in the lysosomal acid lipase gene. Thus, there is an accumulation of lipids in the walls of blood vessels, spleen, and liver. LAL-D is a progressive disease with early mortality due to liver failure, medical complications, and multi-systemic clinical manifestations. Moreover, governments of both developed and developing countries are taking the initiative to make people aware of the LAL-D treatment. Also, pharmaceutical companies are investing more in research and development to provide better treatment for patients. This is anticipated to create lucrative opportunities in the global industry during the forecast period. However, high costs associated with treatment and lack of awareness amongst individuals regarding LAL-D treatment are predicted to hamper the market growth in the coming future.

The current management of LAL-D is majorly focused on nutritional support and nutritional care. The supportive care segment dominated the global market in 2018 mainly because it includes high triglycerides and cholesterol through lipid-lowering statins, low-fat diet, apolipoprotein B production, and management of plasma lipid levels. Along with supportive care, the enzyme replacement therapy (ERT) segment is estimated to grow at the fastest CAGR during the forecast period. This rapid growth is majorly due to high efficiency and long-term disease control post-treatment.

Treatment Takeaway

The cholesteryl ester storage disease (CESD) segment is anticipated to witness the fastest growth during the forecast period. This rapid growth is majorly due to the increasing uptake of ERT and high disease prevalence. In addition, the CSED has a higher prevalence rate than the Wolman disease. On the other hand, the Wolman disease is considered to be of the more severe form, which has an early onset. It occurs due to non-existence of lysosomal acid lipase enzyme activity. There are no clinical signs shown by infants at the time of birth, but after a few months suffer from vomiting, diarrhoea, jaundice, and develop enlarged spleens and livers.

REGIONAL TAKEAWAY

The North America region dominated the global LAL-D treatment market in 2018 followed by Europe. North America is poised to lead the market by the end of 2030 owing to the presence of a large patient pool and high disease prevalence. Europe region is estimated to be the second-largest market owing to the growing occurrence of disease and rising uptake of Kanuma.

Key Vendors Takeaway

Limited therapeutic intervention for LAL-D and increasing eligible patient population is expected to offer a strong commercial opportunity to major industry players to invest in the development of novel treatments in the global market.

Key players of the market include:

Alexion Pharmaceutical Inc.

Merck & Co., Inc.

AstraZeneca plc.

Teva Pharmaceutical Industries Ltd.

Pfizer, Inc.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year - 2015 to 2018

Base Year - 2019

Estimated Year - 2020

Projected Year - 2026

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Government and Regional Agencies

Research Organizations

Consultants

Distributors

Scope of the Report

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET, BY TREATMENT

Lipid Modifying Agents (Statins)

Enzyme Replacement Therapy (ERT)

Stem Cell Therapy

Supportive Care

Surgery

GLOBAL LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET, BY INDICATION

Cholesteryl Ester Storage Disease (CESD)

Wolman Disease (WD)

Others

GLOBAL LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET, BY REGION

North America

The U.S.

Canada

Europe

Germany

France

Italy

Spain

United Kingdom

Rest of Europe

Asia Pacific

India

China

South Korea

Japan

Singapore

Rest of APAC

Latin America

Brazil

Mexico

Argentina

Rest of LATAM

Middle East and Africa

Saudi Arabia

United Arab Emirates

Rest of MEA

TABLE OF CONTENT

1. LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET OVERVIEW

  • 1.1. Study Scope
  • 1.2. Assumption and Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Market Snippet
    • 2.1.1. Market Snippet by Treatment
    • 2.1.2. Market Snippet by Indication
    • 2.1.3. Market Snippet by Region
  • 2.2. Competitive Insights

3. LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT KEY MARKET TRENDS

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT INDUSTRY STUDY

  • 4.1. Porter's Five Forces Analysis
  • 4.2. Marketing Strategy Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis
  • 4.5. COVID-19 Impact Analysis
    • 4.5.1. Pre-COVID-19 Impact Analysis
    • 4.5.2. Post-COVID-19 Impact Analysis

5. LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET LANDSCAPE

  • 5.1. Market Share Analysis
  • 5.2. Key Innovators
  • 5.3. Breakdown Data, by Key manufacturer
    • 5.3.1. Established Player Analysis
    • 5.3.2. Emerging Player Analysis

6. LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET - BY TREATMENT

  • 6.1. Overview
    • 6.1.1. Segment Share Analysis, By Treatment, 2019 & 2026 (%)
  • 6.2. Lipid Modifying Agents (Statins)
    • 6.2.1. Overview
    • 6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 6.3. Enzyme Replacement Therapy (ERT)
    • 6.3.1. Overview
    • 6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 6.4. Stem Cell Therapy
    • 6.4.1. Overview
    • 6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 6.5. Supportive Care
    • 6.5.1. Overview
    • 6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 6.6. Surgery
    • 6.6.1. Overview
    • 6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

7. LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET - BY INDICATION

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Indication, 2019 & 2026 (%)
  • 7.2. Cholesteryl Ester Storage Disease (CESD)
    • 7.2.1. Overview
    • 7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 7.3. Wolman Disease (WD)
    • 7.3.1. Overview
    • 7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 7.4. Others
    • 7.4.1. Overview
    • 7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

8. LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET- BY GEOGRAPHY

  • 8.1. Introduction
    • 8.1.1. Segment Share Analysis, By Region, 2019 & 2026 (%)
  • 8.2. North America
    • 8.2.1. Overview
    • 8.2.2. Key Manufacturers in North America
    • 8.2.3. North America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 8.2.4. North America Market Size and Forecast, By Treatment, 2015 - 2026 (US$ Million)
    • 8.2.5. North America Market Size and Forecast, By Indication, 2015 - 2026 (US$ Million)
    • 8.2.6. U.S.
      • 8.2.6.1. Overview
      • 8.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.2.7. Canada
      • 8.2.7.1. Overview
      • 8.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.3. Europe
    • 8.3.1. Overview
    • 8.3.2. Key Manufacturers in Europe
    • 8.3.3. Europe Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 8.3.4. Europe Market Size and Forecast, By Treatment, 2015 - 2026 (US$ Million)
    • 8.3.5. Europe Market Size and Forecast, By Indication, 2015 - 2026 (US$ Million)
    • 8.3.6. Germany
      • 8.3.6.1. Overview
      • 8.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.3.7. Italy
      • 8.3.7.1. Overview
      • 8.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.3.8. United Kingdom
      • 8.3.8.1. Overview
      • 8.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.3.9. France
      • 8.3.9.1. Overview
      • 8.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.3.10. Rest of Europe
      • 8.3.10.1. Overview
      • 8.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.4. Asia Pacific (APAC)
    • 8.4.1. Overview
    • 8.4.2. Key Manufacturers in Asia Pacific
    • 8.4.3. Asia Pacific Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 8.4.4. Asia Pacific Market Size and Forecast, By Treatment, 2015 - 2026 (US$ Million)
    • 8.4.5. Asia Pacific Market Size and Forecast, By Indication, 2015 - 2026 (US$ Million)
    • 8.4.6. India
      • 8.4.6.1. Overview
      • 8.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.4.7. China
      • 8.4.7.1. Overview
      • 8.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.4.8. Japan
      • 8.4.8.1. Overview
      • 8.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.4.9. South Korea
      • 8.4.9.1. Overview
      • 8.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.4.10. Rest of APAC
      • 8.4.10.1. Overview
      • 8.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.5. Latin America
    • 8.5.1. Overview
    • 8.5.2. Key Manufacturers in Latin America
    • 8.5.3. Latin America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 8.5.4. Latin America Market Size and Forecast, By Treatment, 2015 - 2026 (US$ Million)
    • 8.5.5. Latin America Market Size and Forecast, By Indication, 2015 - 2026 (US$ Million)
    • 8.5.6. Brazil
      • 8.5.6.1. Overview
      • 8.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.5.7. Mexico
      • 8.5.7.1. Overview
      • 8.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.5.8. Argentina
      • 8.5.8.1. Overview
      • 8.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.5.9. Rest of LATAM
      • 8.5.9.1. Overview
      • 8.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Overview
    • 8.6.2. Key Manufacturers in Middle East and Africa
    • 8.6.3. Middle East and Africa Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 8.6.4. Middle East and Africa Market Size and Forecast, By Treatment, 2015 - 2026 (US$ Million)
    • 8.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2015 - 2026 (US$ Million)
    • 8.6.6. Saudi Arabia
      • 8.6.6.1. Overview
      • 8.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.6.7. United Arab Emirates
      • 8.6.7.1. Overview
      • 8.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

9. KEY VENDOR ANALYSIS

  • 9.1. AstraZeneca plc.
    • 9.1.1. Company Snapshot
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Strategic Initiatives
  • 9.2. Alexion Pharmaceutical Inc.
  • 9.3. Merck & Co., Inc.
  • 9.4. Teva Pharmaceutical Industries Ltd.
  • 9.5. Pfizer, Inc.

10. 360 DEGREE ANALYSTVIEW

11. APPENDIX

  • 11.1. Research Methodology
  • 11.2. References
  • 11.3. Abbreviations
  • 11.4. Disclaimer
  • 11.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Lysosomal Acid Liapse (LAL) Deficiency Treatment market: Treatment Snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Treatment
  • TABLE Global Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by Treatment 2015-2026 (USD Million)
  • TABLE Lysosomal Acid Liapse (LAL) Deficiency Treatment market: Indication Snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Indication
  • TABLE Global Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by Indication 2015-2026 (USD Million)
  • TABLE Lysosomal Acid Liapse (LAL) Deficiency Treatment market: Regional snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by Region 2015-2026 (USD Million)
  • TABLE North America Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by Country, 2015-2026 (USD Million)
  • TABLE North America Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by Treatment, 2015-2026 (USD Million)
  • TABLE North America Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by Indication, 2015-2026 (USD Million)
  • TABLE Europe Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by country, 2015-2026 (USD Million)
  • TABLE Europe Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by Treatment, 2015-2026 (USD Million)
  • TABLE Europe Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by Indication, 2015-2026 (USD Million)
  • TABLE Asia Pacific Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by country, 2015-2026 (USD Million)
  • TABLE Asia Pacific Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by Treatment, 2015-2026 (USD Million)
  • TABLE Asia Pacific Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by Indication, 2015-2026 (USD Million)
  • TABLE Latin America Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by country, 2015-2026 (USD Million)
  • TABLE Latin America Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by Treatment, 2015-2026 (USD Million)
  • TABLE Latin America Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by Indication, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by country, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by Treatment, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Lysosomal Acid Liapse (LAL) Deficiency Treatment market, by Indication, 2015-2026 (USD Million)

List of Figures

  • FIGURE Lysosomal Acid Liapse (LAL) Deficiency Treatment market segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2018
  • FIGURE Treatment segment market share analysis, 2019 & 2026
  • FIGURE Treatment segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Lipid Modifying Agents (Statins) segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Enzyme Replacement Therapy (ERT) segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Stem Cell Therapy segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Supportive Care segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Surgery segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Indication segment market share analysis, 2019 & 2026
  • FIGURE Indication segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Cholesteryl Ester Storage Disease (CESD) segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Wolman Disease (WD) segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Regional segment market share analysis, 2019 & 2026
  • FIGURE Regional segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE North America Lysosomal Acid Liapse (LAL) Deficiency Treatment market share and leading players, 2018
  • FIGURE Europe Lysosomal Acid Liapse (LAL) Deficiency Treatment market share and leading players, 2018
  • FIGURE Asia Pacific Lysosomal Acid Liapse (LAL) Deficiency Treatment market share and leading players, 2018
  • FIGURE Latin America Lysosomal Acid Liapse (LAL) Deficiency Treatment market share and leading players, 2018
  • FIGURE Middle East and Africa Lysosomal Acid Liapse (LAL) Deficiency Treatment market share and leading players, 2018
  • FIGURE North America Lysosomal Acid Liapse (LAL) Deficiency Treatment market share analysis by country, 2018
  • FIGURE U.S. Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Canada Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Europe Lysosomal Acid Liapse (LAL) Deficiency Treatment market share analysis by country, 2018
  • FIGURE Germany Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Spain Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Italy Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE UK Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE France Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rest of the Europe Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Asia Pacific Lysosomal Acid Liapse (LAL) Deficiency Treatment market share analysis by country, 2018
  • FIGURE India Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE China Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Japan Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE South Korea Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Singapore Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rest of APAC Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Latin America Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Latin America Lysosomal Acid Liapse (LAL) Deficiency Treatment market share analysis by country, 2018
  • FIGURE Brazil Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Mexico Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Argentina Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rest of LATAM Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Middle East and Africa Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Middle East and Africa Lysosomal Acid Liapse (LAL) Deficiency Treatment market share analysis by country, 2018
  • FIGURE Saudi Arabia Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE United Arab Emirates Lysosomal Acid Liapse (LAL) Deficiency Treatment market size, forecast and trend analysis, 2015 to 2026 (USD Million)